Key result
New antiviral agents and modified regimens have improved treatment efficacy across multiple viral infections, including sustained-response rates up to 60% for hepatitis C with interferon-ribavirin.
Advances in antiviral therapy, such as neuraminidase inhibitors for influenza and combination interferon-ribavirin for hepatitis C, have significantly improved treatment efficacy and dosing convenience.
No takes yet. Share an insight, caveat, or question.
May guide antiviral selection in hepatitis C and influenza; leaves open need for randomized confirmation before broader adoption.
William D . Rawlinson (2001) conducted a review in Influenza, hepatitis C, herpesvirus, enterovirus, and rhinovirus infections. Antiviral agents was evaluated. New antiviral agents and modified regimens have improved treatment efficacy across multiple viral infections, including sustained-response rates up to 60% for hepatitis C with interferon-ribavirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: